Pricing

CTI BioPharma Corp (CTIC)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Adam R. Craig
Employees:
120
3101 WESTERN AVENUE, SUITE 800, SEATTLE, WA, 98121
2062827100
    Formally known as:
  • Cell Therapeutics, Inc.
Stock Split History
DateRatio
2007-04-16 1:4
2008-09-02 1:1
2011-05-16 1:6
2012-09-04 1:5
2017-01-03 1:10
CTI BioPharma Corp. focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available